Sangamo Therapeutics, Inc.SGMONASDAQ
Loading
R&D Expense Growth TrendStable
Percentile Rank44
3Y CAGR-22.8%
5Y CAGR-15.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-22.8%/yr
vs +20.7%/yr prior
5Y CAGR
-15.5%/yr
Recent deceleration
Acceleration
-43.5pp
Decelerating
Percentile
P44
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 qtr
Consecutive declineStable
| Period | Value |
|---|---|
| Q3 2025 | 3.91% |
| Q2 2025 | 4.15% |
| Q1 2025 | 9.85% |
| Q4 2024 | -14.63% |
| Q3 2024 | 14.49% |
| Q2 2024 | -32.51% |
| Q1 2024 | -29.22% |
| Q4 2023 | -11.18% |
| Q3 2023 | -9.45% |
| Q2 2023 | -0.27% |
| Q1 2023 | -4.48% |
| Q4 2022 | 1.63% |
| Q3 2022 | 8.49% |
| Q2 2022 | 2.45% |
| Q1 2022 | 13.09% |
| Q4 2021 | -17.12% |
| Q3 2021 | 4.01% |
| Q2 2021 | 6.47% |
| Q1 2021 | 7.78% |
| Q4 2020 | 15.61% |
| Q3 2020 | 9.06% |
| Q2 2020 | 0.11% |
| Q1 2020 | 8.22% |
| Q4 2019 | 5.62% |
| Q3 2019 | -0.46% |
| Q2 2019 | 4.61% |
| Q1 2019 | 4.80% |
| Q4 2018 | 15.43% |
| Q3 2018 | -1.52% |
| Q2 2018 | 24.24% |
| Q1 2018 | 21.52% |
| Q4 2017 | 5.17% |
| Q3 2017 | 22.96% |
| Q2 2017 | 15.78% |
| Q1 2017 | -6.83% |
| Q4 2016 | -18.33% |
| Q3 2016 | -12.57% |
| Q2 2016 | 27.43% |
| Q1 2016 | -23.31% |
| Q4 2015 | 19.24% |